RT Journal Article
SR Electronic
T1 Virological assessment of hospitalized cases of coronavirus disease 2019
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.05.20030502
DO 10.1101/2020.03.05.20030502
A1 Wölfel, Roman
A1 Corman, Victor M.
A1 Guggemos, Wolfgang
A1 Seilmaier, Michael
A1 Zange, Sabine
A1 Müller, Marcel A.
A1 Niemeyer, Daniela
A1 Kelly, Terence C. Jones
A1 Vollmar, Patrick
A1 Rothe, Camilla
A1 Hoelscher, Michael
A1 Bleicker, Tobias
A1 Brünink, Sebastian
A1 Schneider, Julia
A1 Ehmann, Rosina
A1 Zwirglmaier, Katrin
A1 Drosten, Christian
A1 Wendtner, Clemens
YR 2020
UL http://medrxiv.org/content/early/2020/03/08/2020.03.05.20030502.abstract
AB Coronavirus disease 2019 (COVID-19) is an acute respiratory tract infection that emerged in late 20191,2. Initial outbreaks in China involved 13.8% cases with severe-, and 6.1% with critical courses3. This severe presentation corresponds to the usage of a virus receptor that is expressed predominantly in the lung2,4. By causing an early onset of severe symptoms, this same receptor tropism is thought to have determined pathogenicity but also aided the control of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of COVID-19 cases with mild upper respiratory tract symptoms, suggesting a potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on body site - specific virus replication, immunity, and infectivity. Here we provide a detailed virological analysis of nine cases, providing proof of active virus replication in upper respiratory tract tissues. Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 × 108 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-derived samples, but not from stool samples in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat- and lung samples of one same patient. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 6-12 days, but was not followed by a rapid decline of viral loads. COVID-19 can present as a mild upper respiratory tract illness. Active virus replication in the upper respiratory tract puts prospects of COVID-19 containment in perspective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the German Ministry of Research (01KI1723A) and the European Union (602525) to C. D. as well as by the German Bundeswehr Medical ServiceBiodefense Research Program. The funders had no role in study design, data collection and analysis or decision to publish. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the manuscript and the Annex.